ClinicalTrials.gg
CompletedNCT00969150Updated Oct 25, 2013Results posted

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

A Phase 3 interventional study of Levomilnacipran ER and Placebo in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 25 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-10-25.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
362
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.

Enrollment
10th of 14
362 · median 472
Started
2009
with 3 others
Phase 3
10 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
9 of 14
Forest Laboratories

Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 10th largest by enrollment, is one of 4 that started in 2009, is one of 10 in phase 3, and was the 1st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →

Where they have run

About levomilnacipran

Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing levomilnacipran in Depressive Disorder, Major as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Depression
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, 18-80 years old
  • Currently meet the criteria for Major Depressive Disorder
  • The patient's current depressive episode must be at least 4 weeks in duration

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, women who will be breastfeeding during the study, and women with who are not practicing a reliable method of
  • Patients with a history of meeting criteria for:

    • any manic or hypomanic episode
    • schizophrenia or any other psychotic disorder
    • obsessive-compulsive disorder
  • Patients who are considered a suicide risk
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
362 participants (actual)

Study arms

  • Placebo comparator
    2

    Matching placebo capsules, oral administration, once daily dosing.

    Drug: Placebo

  • Experimental
    1

    Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.

    Drug: Levomilnacipran ER

Interventions

  • Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.

  • DrugPlacebo

    Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity).

    Time frame: From Baseline to Week 8

Secondary outcomes

  1. Change in Sheehan Disability Scale (SDS) Total Score

    The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe)

    Time frame: From Baseline to Week 8

07

Results

Posted Oct 25, 2013

Participant flow

Patient were recruited over a 12-month period from September of 2009 to September of 2010 at 24 studies sites in the United States.

Participant flow — Overall Study
MilestonePlaceboLevomilnacipran ER
Started182175
Completed149135
Not completed3340
Withdrew: Adverse event414
Withdrew: Lack of efficacy11
Withdrew: Protocol violation912
Withdrew: Withdrawal by subject139
Withdrew: Lost to follow-up54
Withdrew: Other reasons10

Outcome measures

PrimaryChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity).

Time frame:
From Baseline to Week 8
Reported as:
Least squares mean · units on a scale
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
units on a scalePlaceboLevomilnacipran ER
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-14.2 ± 0.90-15.7 ± 0.94
Statistical analysis
  • Placebo vs Levomilnacipran ER · Mixed Models Analysis · p = 0.2492 · Least squares mean difference: -1.49 · 95% CI -4.02 to 1.05Mixed-effects model for repeated measures.
SecondaryChange in Sheehan Disability Scale (SDS) Total Score

The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe)

Time frame:
From Baseline to Week 8
Reported as:
Least squares mean · units on a scale
Change in Sheehan Disability Scale (SDS) Total Score
units on a scalePlaceboLevomilnacipran ER
Change in Sheehan Disability Scale (SDS) Total Score-8.2 ± 0.67-8.8 ± 0.68
Statistical analysis
  • Placebo vs Levomilnacipran ER · Mixed Models Analysis · p = 0.5625 · Least squares mean difference: -0.54 · 95% CI -2.38 to 1.29Mixed-effects model for repeated measures.

Adverse events

Collected over Adverse event data was collection over a 14-month period from September 2009 to November 2010 at 24 study sites in the U.S.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/182 (0.5%)58/182 (31.9%)
Levomilnacipran ER—0/175 (0%)90/175 (51.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboLevomilnacipran ER
Blood Pressure IncreasedInvestigations1/1820/175
Chest PainGeneral disorders1/1820/175
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboLevomilnacipran ER
NauseaGastrointestinal disorders6/18230/175
HeadacheNervous system disorders22/18228/175
Dry mouthGastrointestinal disorders11/18214/175
Ejaculation disorderReproductive system and breast disorders0/666/76
InsomniaPsychiatric disorders13/18212/175
HyperhidrosisSkin and subcutaneous tissue disorders2/18212/175
DizzinessNervous system disorders3/18211/175
Upper respiratory tract infectionInfections and infestations11/1826/175
VomitingGastrointestinal disorders1/18210/175
Erectile dysfunctionReproductive system and breast disorders1/664/76

Baseline characteristics

While a total of 362 patients were randomized to receive double-blind treatment, 5 of these patients were either lost to follow up or withdrew consent before receiving double-blind treatment. The Baseline Participant population is based on the 357 randomized patients who went on to receive double-blind treatment (Safety Population).

Age Continuous
Age Continuous(years)PlaceboLevomilnacipran ERTotal
Mean43.7 ± 13.342.8 ± 12.943.3 ± 13.1
Age, Customized
Age, Customized(participants)PlaceboLevomilnacipran ERTotal
18 years to 19 years213
20 years to 29 years333467
30 years to 39 years353267
40 years to 49 years4753100
50 years to 59 years403777
60 years to 80 years251843
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLevomilnacipran ERTotal
Female11699215
Male6676142
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLevomilnacipran ERTotal
White149133282
Black or African American282957
Asian347
American Indian or Alaska native033
Other268
Hispanic or Latino181634
Not Hispanic or Latino164159323
Region of Enrollment
Region of Enrollment(participants)PlaceboLevomilnacipran ERTotal
United States182175357
Weight
Weight(kg)PlaceboLevomilnacipran ERTotal
Mean82.9 ± 18.082.4 ± 18.182.7 ± 18.0
Body Mass Index (BMI)
Body Mass Index (BMI)(Kilograms Per Meter Squared)PlaceboLevomilnacipran ERTotal
Mean28.9 ± 5.728.7 ± 5.428.8 ± 5.5
08

Study locations

25 sites
  • Forest Investigative Site
    Scottsdale, Arizona 85254, United States
  • Forest Investigative Site
    Encino, California 91316, United States
  • Forest Investigative Site
    Los Alamitos, California 90720, United States
  • Forest Investigative Site
    Oceanside, California 92056, United States
  • Forest Investigative Site
    Denver, Colorado 80204, United States
  • Forest Investigative Site
    Denver, Colorado 80239, United States
  • Forest Investigative Site
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site
    Orlando, Florida 32806, United States
  • Forest Investigative Site
    Chicago, Illinois 60634, United States
  • Forest Investigative Site
    Wichita, Kansas 67206, United States
  • Forest Investigative Site
    Glen Burnie, Maryland 21061, United States
  • Forest Investigative Site
    Fall River, Massachusetts 02721, United States
  • Forest Investigative Site
    East Lansing, Michigan 48824, United States
  • Forest Investigative Site
    Cherry Hill, New Jersey 08002, United States
  • Forest Investigative Site
    Brooklyn, New York 11235, United States
  • Forest Investigative Site
    New York, New York 10021, United States
  • Forest Investigative Site
    Staten Island, New York 10312, United States
  • Forest Investigative Site 013
    Canton, Ohio 44718, United States
  • Forest Investigative Site
    Dayton, Ohio 45417, United States
  • Forest Investigative Site
    Portland, Oregon 97210, United States
  • Forest Investigative Site
    Philadelphia, Pennsylvania 19107, United States
  • Forest Investigative Site
    Lincoln, Rhode Island 02865, United States
  • Forest Investigative Site
    Woodstock, Vermont 05091, United States
  • Forest Investigative Site
    Bellevue, Washington 98007, United States
  • Forest Investigative Site
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Cutler AJ, Gommoll CP, Chen C, Greenberg WM, Ruth A. Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories. Prim Care Companion CNS Disord. 2015 Jun 11;17(3):10.4088/PCC.14m01753. doi: 10.4088/PCC.14m01753. eCollection 2015. PubMed 26644957 ↗
  • Gommoll CP, Greenberg WM, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J Drug Assess. 2014 Jan 16;3(1):10-9. doi: 10.3109/21556660.2014.884505. eCollection 2014. PubMed 27536449 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009 and a primary completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 2 years 11 months after primary completion. A results delay was requested in Mar 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2009
First posted
Sep 1, 2009
Start
Sep 2009
Primary completionActual
Nov 2010
Results delay requested
Mar 1, 2012
Results first posted
Oct 25, 2013
Last update
Oct 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00969150
Responsible party
Sponsor
First posted
Sep 1, 2009
Start date
Sep 2009
Primary completion
Nov 2010
Results posted
Oct 25, 2013
Last update
Oct 25, 2013

Study contacts

Carl Gommoll, MS
study director · Forest Research Institute, a subsidiary of Forest Laboratories, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levomilnacipran

Start the discussion